TY - JOUR
T1 - GnRH-antagonist programming versus GnRH agonist protocol
T2 - A randomized trial
AU - Hershko Klement, Anat
AU - Berkovitz, Arie
AU - Wiser, Amir
AU - Gonen, Ofer
AU - Amichay, Keren
AU - Cohen, Ilan
AU - Ghetler, Yehudith
AU - Shulman, Adrian
N1 - Publisher Copyright:
© 2014 Elsevier Ireland Ltd. All rights reserved.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Objective Testing the ability to program IVF GnRH-antagonist cycles to avoid weekend oocyte retrieval. Study design Preliminary randomized clinical trial. Patients presenting an indication for IVF or IVF-ICSI were assigned into either the Treatment Group - GnRH antagonist protocol, programmed to start stimulatory agents on a Friday, with oral 2 mg estradiol valerate twice a day from the 2nd day of cycle until the first Friday to follow, or to the Control Group - long luteal GnRH agonist protocol. Results The performance of 27 Treatment Group patients and 24 Control Group patients was analyzed. Cycle dynamics were not clinically or statistically different except for a significant difference in the number of follicles measuring ≥18 mm on hCG administration day. There were no differences in the number of aspirated ova, fertilization rates, embryo quality or number of embryos to be transferred. Pregnancy rate was 41.7% in the Treatment Group and 50% in the Control Group (P > 0.5). Only one patient assigned to the Treatment Group had a weekend retrieval. Conclusions Preliminary results demonstrate no compromise related to follicular estrogen programming in a GnRH antagonist protocol and provide reassurance regarding the ability to achieve programming goals.
AB - Objective Testing the ability to program IVF GnRH-antagonist cycles to avoid weekend oocyte retrieval. Study design Preliminary randomized clinical trial. Patients presenting an indication for IVF or IVF-ICSI were assigned into either the Treatment Group - GnRH antagonist protocol, programmed to start stimulatory agents on a Friday, with oral 2 mg estradiol valerate twice a day from the 2nd day of cycle until the first Friday to follow, or to the Control Group - long luteal GnRH agonist protocol. Results The performance of 27 Treatment Group patients and 24 Control Group patients was analyzed. Cycle dynamics were not clinically or statistically different except for a significant difference in the number of follicles measuring ≥18 mm on hCG administration day. There were no differences in the number of aspirated ova, fertilization rates, embryo quality or number of embryos to be transferred. Pregnancy rate was 41.7% in the Treatment Group and 50% in the Control Group (P > 0.5). Only one patient assigned to the Treatment Group had a weekend retrieval. Conclusions Preliminary results demonstrate no compromise related to follicular estrogen programming in a GnRH antagonist protocol and provide reassurance regarding the ability to achieve programming goals.
KW - Drug administration schedule
KW - In vitro fertilization
KW - Oocyte retrieval
KW - Patient schedule
KW - Pituitary hormone release inhibiting hormones
UR - http://www.scopus.com/inward/record.url?scp=84921326209&partnerID=8YFLogxK
U2 - 10.1016/j.ejogrb.2014.12.021
DO - 10.1016/j.ejogrb.2014.12.021
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25594526
AN - SCOPUS:84921326209
SN - 0301-2115
VL - 185
SP - 170
EP - 173
JO - European Journal of Obstetrics and Gynecology and Reproductive Biology
JF - European Journal of Obstetrics and Gynecology and Reproductive Biology
ER -